KR20240124950A - 보체 인자-i 제제 - Google Patents
보체 인자-i 제제 Download PDFInfo
- Publication number
- KR20240124950A KR20240124950A KR1020247022975A KR20247022975A KR20240124950A KR 20240124950 A KR20240124950 A KR 20240124950A KR 1020247022975 A KR1020247022975 A KR 1020247022975A KR 20247022975 A KR20247022975 A KR 20247022975A KR 20240124950 A KR20240124950 A KR 20240124950A
- Authority
- KR
- South Korea
- Prior art keywords
- cfi
- preparation
- formulation
- present
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21045—Complement factor I (3.4.21.45)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293013P | 2021-12-22 | 2021-12-22 | |
| US63/293,013 | 2021-12-22 | ||
| PCT/US2022/082179 WO2023122691A1 (en) | 2021-12-22 | 2022-12-21 | Complement factor-i formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240124950A true KR20240124950A (ko) | 2024-08-19 |
Family
ID=85172701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247022975A Pending KR20240124950A (ko) | 2021-12-22 | 2022-12-21 | 보체 인자-i 제제 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250009855A1 (https=) |
| EP (1) | EP4452321A1 (https=) |
| JP (1) | JP2025503483A (https=) |
| KR (1) | KR20240124950A (https=) |
| CN (1) | CN118450906A (https=) |
| AU (1) | AU2022420007A1 (https=) |
| CA (1) | CA3241714A1 (https=) |
| IL (1) | IL313777A (https=) |
| MX (1) | MX2024007731A (https=) |
| WO (1) | WO2023122691A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| WO2021081348A1 (en) * | 2019-10-23 | 2021-04-29 | Gemini Therapeutics Inc. | Methods for treating patients having cfi mutations with recombinant cfi proteins |
| CA3182800A1 (en) * | 2020-06-14 | 2021-12-23 | Vertex Pharmaceuticals Inc. | Complement factor i-related compositions and methods |
-
2022
- 2022-12-21 IL IL313777A patent/IL313777A/en unknown
- 2022-12-21 EP EP22854364.1A patent/EP4452321A1/en active Pending
- 2022-12-21 WO PCT/US2022/082179 patent/WO2023122691A1/en not_active Ceased
- 2022-12-21 CA CA3241714A patent/CA3241714A1/en active Pending
- 2022-12-21 MX MX2024007731A patent/MX2024007731A/es unknown
- 2022-12-21 JP JP2024537890A patent/JP2025503483A/ja active Pending
- 2022-12-21 AU AU2022420007A patent/AU2022420007A1/en active Pending
- 2022-12-21 KR KR1020247022975A patent/KR20240124950A/ko active Pending
- 2022-12-21 CN CN202280084962.2A patent/CN118450906A/zh active Pending
-
2024
- 2024-06-21 US US18/750,927 patent/US20250009855A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022420007A1 (en) | 2024-06-20 |
| WO2023122691A1 (en) | 2023-06-29 |
| EP4452321A1 (en) | 2024-10-30 |
| IL313777A (en) | 2024-08-01 |
| JP2025503483A (ja) | 2025-02-04 |
| US20250009855A1 (en) | 2025-01-09 |
| CN118450906A (zh) | 2024-08-06 |
| MX2024007731A (es) | 2024-07-01 |
| CA3241714A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12178861B2 (en) | Stabilized liquid and lyophilized ADAMTS13 formulations | |
| US20240058263A1 (en) | Formulations of antibody | |
| RU2731418C2 (ru) | Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине | |
| KR100942399B1 (ko) | Egf 수용체에 대한 항체를 함유하는 동결건조된 제제 | |
| KR20180100439A (ko) | 이중특이적 항체 작제물을 포함하는 약제학적 조성물 | |
| US12428464B2 (en) | Stable fusion protein formulation | |
| JPWO2008029908A1 (ja) | 抗体を含有する安定な凍結乾燥医薬製剤 | |
| TWI752912B (zh) | 那他珠單抗的穩定水性調配物 | |
| KR20240124950A (ko) | 보체 인자-i 제제 | |
| JP2025509059A (ja) | α-ガラクトシダーゼAの融合タンパク質を含む凍結乾燥製剤 | |
| WO2012144579A1 (ja) | 溶液状抗体製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |